| Identification | Back Directory | [Name]
N-(4-BROMOPHENYL)-3-{[(4-BROMOPHENYL)AMI | [CAS]
300670-16-0 | [Synonyms]
C2-8
(polyQ aggregation inhibitor C2-8)
N-(4-BROMOPHENYL)-3-{[(4-BROMOPHENYL)AMI
Polyglutamine Aggregation Inhibitor III, C2-8
Benzamide, N-(4-bromophenyl)-3-(((4-bromophenyl)amino)sulfonyl)
N-(4-Bromophenyl)-3-[[(4-bromophenyl)amino]sulfonyl]benzamide >=98% (HPLC), solid | [Molecular Formula]
C19H14Br2N2O3S | [MDL Number]
MFCD00355835 | [MOL File]
300670-16-0.mol | [Molecular Weight]
510.2 |
| Chemical Properties | Back Directory | [density ]
1.760±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: ~20 mg/mL | [form ]
solid | [pka]
7.49±0.10(Predicted) | [color ]
off-white |
| Hazard Information | Back Directory | [Description]
C2-8 is an inhibitor of polyglutamine (polyQ) aggregation (IC50s = 25 and 0.05 μM for recombinant HDQ51 and in PC12 cells, respectively). It also inhibits polyQ aggregation in organotypic hippocampal slice cultures isolated from R6/2 transgenic mice and reduces neurodegeneration in a dose-dependent manner in a Drosophila model of Huntington''s disease. C2-8 (100 and 200 mg/kg) reduces huntingtin aggregate size, reduces neuronal atrophy, and improves motor performance in a rotarod test in the R6/2 transgenic mouse model of Huntington''s disease. | [Uses]
C2-8 is an inhibitor of polyglutamine (polyQ) aggregation (IC50s=25 and 0.05 μM for recombinant HDQ51 and in PC12 cells, respectively). It also inhibits polyQ aggregation in organotypic hippocampal slice cultures isolated from R6/2 transgenic mice and reduces neurodegeneration in a dose-dependent manner in a Drosophila model of Huntington's disease. C2-8 (100 and 200 mg/kg) reduces huntingtin aggregate size, reduces neuronal atrophy, and improves motor performance in a rotarod test in the R6/2 transgenic mouse model of Huntington's disease. | [storage]
Store at -20°C | [References]
[1] Zhang, et al. A potent small molecule inhibits polyglutamine aggregation in Huntington’s disease neurons and suppresses neurodegeneration in vivo. Proc. Natl. Acad. Sci. USA 102(3), 892-897 (2005). |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
| Company Name: |
Alexis Corporation
|
| Tel: |
+41 61 926 8989 |
| Website: |
www.alexis-biochemicals.com |
|